Literature DB >> 30918958

Endocrine and Metabolic Diseases Among Colorectal Cancer Survivors in a Population-Based Cohort.

Makenzie L Hawkins1, Brenna E Blackburn1, Kerry Rowe2, John Snyder2, Vikrant G Deshmukh3, Michael Newman3, Alison Fraser4, Ken Smith4, Kimberly Herget5, Patricia A Ganz6, N Jewel Samadder7, Mia Hashibe1,5.   

Abstract

BACKGROUND: There are an estimated 1.4 million colorectal cancer (CRC) survivors in the United States. Research on endocrine and metabolic diseases over the long term in CRC survivors is limited. Obesity is a risk factor for CRC; thus it is of interest to investigate diseases that may share this risk factor, such as diabetes, for long-term health outcomes among CRC survivors.
METHODS: A total of 7114 CRC patients were identified from the Utah Population Database and matched to a general population cohort of 25 979 individuals on birth year, sex, and birth state. Disease diagnoses (assessed over three time periods of 1-5 years, 5-10 years, and >10 years) were identified using electronic medical records and statewide ambulatory and inpatient discharge data. Cox proportional hazard models were used to estimate the risk of endocrine and metabolic disease.
RESULTS: Across all three time periods, risks for endocrine and metabolic diseases were statistically significantly greater for CRC survivors compared with the general population cohort. At 1-5 years postdiagnosis, CRC survivors' risk for diabetes mellitus with complications was statistically significantly elevated (hazard ratio [HR] = 1.36, 99% confidence interval [CI] = 1.09 to 1.70). CRC survivors also experienced a 40% increased risk of obesity at 1-5 years postcancer diagnosis (HR= 1.40, 99% CI= 1.66 to 2.18) and a 50% increased risk at 5-10 years postdiagnosis (HR = 1.50, 99% CI= 1.16 to 1.95).
CONCLUSIONS: Endocrine and metabolic diseases were statistically significantly higher in CRC survivors throughout the follow-up periods of 1-5 years, 5-10 years, and more than 10 years postdiagnosis. As the number of CRC survivors increases, understanding the long-term trajectory is critical for improved survivorship care.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2020        PMID: 30918958     DOI: 10.1093/jnci/djz040

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  4 in total

Review 1.  Higher Incidence of Diabetes in Cancer Patients Compared to Cancer-Free Population Controls: A Systematic Review and Meta-Analysis.

Authors:  Keyi Yang; Zhunzhun Liu; Melissa S Y Thong; Daniela Doege; Volker Arndt
Journal:  Cancers (Basel)       Date:  2022-04-02       Impact factor: 6.639

Review 2.  Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Aleksandra Stefanovic; Rosaria Vincenza Giglio; Marcello Ciaccio; Manfredi Rizzo
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 6.208

3.  Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19.

Authors:  Magda Bucholc; Declan Bradley; Damien Bennett; Lynsey Patterson; Rachel Spiers; David Gibson; Hugo Van Woerden; Anthony J Bjourson
Journal:  Sci Rep       Date:  2022-10-15       Impact factor: 4.996

4.  Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study.

Authors:  Dominik J Ose; Richard Viskochil; Andreana N Holowatyj; Mikaela Larson; Dalton Wilson; William A Dunson; Vikrant G Deshmukh; J Ryan Butcher; Belinda R Taylor; Kim Svoboda; Jennifer Leiser; Benjamin Tingey; Benjamin Haaland; David W Wetter; Simon J Fisher; Mia Hashibe; Cornelia M Ulrich
Journal:  J Natl Compr Canc Netw       Date:  2021-03-10       Impact factor: 11.908

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.